⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13984967 | 0.74 | — | — | |
| SCHEMBL31495236 | 0.74 | — | — | |
| SCHEMBL36982 | 0.74 | — | — | |
| SCHEMBL5320771 | 0.72 | L3MBTL1 (0.50) | — | |
| SCHEMBL28484406 | 0.72 | L3MBTL1 (0.50) | — | |
| SCHEMBL18037706 | 0.70 | — | — | |
| SCHEMBL19903723 | 0.70 | — | — | |
| SCHEMBL22516444 | 0.70 | — | — | |
| SCHEMBL1095503 | 0.70 | — | — | |
| SCHEMBL1095093 | 0.70 | L3MBTL1 (1.00) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951098-B2 | Synthesis of 5-azacytidine | PHARMION LLC (US) | 2018-04-24 | — | — | US | disclosed |
| EP-2691408-B1 | SYNTHESIS OF 5-AZACYTIDINE | CELGENE INT SÁRL (CH) | 2017-06-28 | — | — | EP | disclosed |
| US-20140128593-A1 | SYNTHESIS OF 5-AZACYTIDINE | CELGENE INTERNATIONAL SARL (US) | 2014-05-08 | — | — | US | disclosed |
| EP-2691408-A1 | SYSTHESIS OF 5-AZACYTIDINE | Celgene International SÁRL (CH) | 2014-02-05 | — | — | EP | disclosed |
| WO-2012135405-A1 | SYSTHESIS OF 5-AZACYTIDINE | PHARMION LLC (US) | 2012-10-04 | — | — | WO | disclosed |
| US-8153787-B2 | Azacytosine derivatives useful as antiviral agents | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2012-04-10 | — | — | US | disclosed |
| US-8153787-B2 | Azacytosine derivatives useful as antiviral agents | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2012-04-10 | — | — | US | disclosed |
| US-8153787-B2 | Azacytosine derivatives useful as antiviral agents | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2012-04-10 | — | — | US | disclosed |
| EP-1966226-B1 | AZACYTOSINE DERIVATIVES USEFUL AS ANTIVIRAL AGENTS | LEUVEN K U RES & DEV (BE) | 2010-11-10 | — | — | EP | disclosed |
| EP-1966226-B1 | AZACYTOSINE DERIVATIVES USEFUL AS ANTIVIRAL AGENTS | LEUVEN K U RES & DEV (BE) | 2010-11-10 | — | — | EP | disclosed |
| US-20090005346-A1 | Azacytosine Derivatives Useful as Antiviral Agents | K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) | 2009-01-01 | — | — | US | disclosed |
| EP-1966226-A2 | AZACYTOSINE DERIVATIVES USEFUL AS ANTIVIRAL AGENTS | K.U.Leuven Research & Development (BE) | 2008-09-10 | — | — | EP | disclosed |
| US-20070207973-A1 | 1,3,5-Triazines for Treatment of Viral Diseases | KORONIS PHARMACEUTICALS, INCORPORATED (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070142310-A1 | 1,3,5-TRIAZINES FOR TREATMENT OF VIRAL DISEASES | KORONIS PHARMACEUTICALS, INCORPORATED (US) | 2007-06-21 | — | — | US | disclosed |
| US-20070142310-A1 | 1,3,5-TRIAZINES FOR TREATMENT OF VIRAL DISEASES | KORONIS PHARMACEUTICALS, INCORPORATED (US) | 2007-06-21 | — | — | US | disclosed |
| WO-2007065231-A2 | AZACYTOSINE DERIVATIVES USEFUL AS ANTIVIRAL AGENTS | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2007-06-14 | — | — | WO | disclosed |
| WO-2007065231-A2 | AZACYTOSINE DERIVATIVES USEFUL AS ANTIVIRAL AGENTS | K.U. LEUVEN RESEARCH & DEVELOPMENT (BE) | 2007-06-14 | — | — | WO | disclosed |
| EP-1545558-A2 | 1, 3, 5-TRIAZINES FOR TREATMENT OF VIRAL DISEASES | Koronis Pharmaceuticals, Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040127436-A1 | 1,3,5-Triazines for treatment of viral diseases | KORONIS PHARMACEUTICALS, INC. (US) | 2004-07-01 | — | — | US | disclosed |
| WO-2004028454-A2 | 1, 3, 5-TRIAZINES FOR TREATMENT OF VIRAL DISEASES | KORONIS PHARMACEUTICALS, INCORPORATED (US) | 2004-04-08 | — | — | WO | disclosed |